The client’s goal focused on identifying, reaching and influencing target patient populations suffering from knee pain who might benefit from a non-steroidal anti-inflammatory drug. Furthermore, the client needed a third-party provider of social media activation technology to test the effectiveness of finding and influencing patients on social media, as well as answer key questions about the viability of reaching patients in emerging markets.
Growing Patient Engagement through Social Media Activation Technology
Leveraging iSwarm, an innovative social media listening and activation technology that finds and engages patients on a global scale, EPAM helped a leading multinational pharmaceutical company connect its patients in emerging markets suffering from knee pain with one of the client’s pain relief drugs.
With iSwarm, EPAM was able to identify 54,000+ people per annum who fit a predetermined patient persona and, as a result, represented the client’s target audience in the Latin American (LA) and Asian Pacific (AP) emerging markets. From there, EPAM helped the client serve social media ads to the target patient population, which led social media users to a landing page full of information to help them improve their health and relieve knee pain.
'Engage' Stage Results
|Knee Pain Prevalence
|Active Twitter Users
||F: 45% – M: 55%
||F: 64% – M: 34%
EPAM helped the client to analyze millions of digital conversations across the two countries. Furthermore, iSwarm presents a new method of marketing in pharma that is not only measurable in terms of ROI, but also successful in connecting patients with the potentially life-saving drugs and clinical trials they need. With iSwarm, pharma companies can finally reach targeted patient populations and have a detailed view of the effectiveness of a social or digital marketing campaign.